"HN Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein from Sendai, para-influenza, Newcastle Disease, and other viruses that participates in binding the virus to cell-surface receptors. The HN protein possesses both hemagglutinin and neuraminidase activity.
| Descriptor ID |
D015707
|
| MeSH Number(s) |
D12.776.964.970.880.350 D23.050.327.461.350
|
| Concept/Terms |
HN Protein- HN Protein
- Protein, HN
- HANA Glycoprotein
- Glycoprotein, HANA
- Hemagglutinin-Neuraminidase Glycoprotein
- Glycoprotein, Hemagglutinin-Neuraminidase
- Hemagglutinin Neuraminidase Glycoprotein
|
Below are MeSH descriptors whose meaning is more general than "HN Protein".
Below are MeSH descriptors whose meaning is more specific than "HN Protein".
This graph shows the total number of publications written about "HN Protein" by people in this website by year, and whether "HN Protein" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "HN Protein" by people in Profiles.
-
Quantitative comparison of human parainfluenza virus hemagglutinin-neuraminidase receptor binding and receptor cleavage. J Virol. 2013 Aug; 87(16):8962-70.
-
A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Proteins. 1995 Oct; 23(2):264-77.
-
Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine. 1995 Aug; 13(12):1095-101.
-
Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine. 1994 May; 12(6):551-6.
-
Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis. 1993 Jan; 167(1):191-5.